HexaCard allows the identification of clonality and provides a genetic ID card for each clone or batch, ensuring the integrity and accuracy of the entire production pipeline.
BAGNEUX, France, July 18, 2023 / B3C newswire / -- Genomic Vision (FR0011799907 – GV, – the “Company”), a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, is pleased to announce the launch of its new service, HexaCard.
HexaCard is a powerful solution for the control and optimization of genome editing, mainly used in gene therapy and biomanufacturing applications. The service addresses the prevalent challenges of cellular cross-contamination, misidentified cell lines, and the use of cell cultures at high passage levels which often result in inaccurate and misleading results, as well as the waste of valuable resources.
HexaCard allows the characterization of genetic material as a quality control requirement for biomanufacturing based on the analysis of six parameters, all integrated into one single assay: copy number determination, orientation assessment, integration site identification, evaluation of the genetic integrity in the target region, analyzing on/off target insertions, and establishing a genetic signature for stability assessment. HexaCard thus ensures the selection of the best clones, enhancing the productivity and stability while reducing turnaround time and costs.
With HexaCard, contract manufacturing organizations (CMOs) and gene therapy companies and researchers can confidently optimize their processes, make informed decisions, and mitigate the risks associated with inaccurate cell line characterization. By enabling the identification of clonality and providing a genetic ID card for each clone or batch, HexaCard ensures the integrity and accuracy of the entire production pipeline.
Prakhar Bisht, Principal Scientist, Genomic Vision (R&D Department), said: "Genomic Vision's HexaCard service empowers researchers and biomanufacturers with a groundbreaking solution to overcome the challenges of cell line characterization. By providing an accurate genetic ID card for each clone or batch, we eliminate the risks associated with cellular cross-contamination and misidentification. This allows our customers to boost productivity, ensure stability, and ultimately deliver high-quality products, while reducing both turnaround time and costs.”
HexaCard aims to consolidate multiple technologies used in assessing engineered genome modifications, offering a streamlined, one-stop-shop solution for the cell and gene therapy and biomanufacturing industries. HexaCard is based on the Company’s proprietary Molecular Combing Technology (MCT) which allows the structural, functional and dynamic study of the human genome and offers a unique tool for characterizing genetically modified cells. Together with its AI-based analysis software FiberSmart®, Genomic Vision offers unique tools for the characterization of genetically modified cells including the generation of comprehensive reports and statistical plots, to empower researches with quantitative decision-making capabilities.
Genomic Vision continues to implement its refocused strategy in the bioproduction, cell and gene therapy arenas. Leveraging its technology, Genomic Vision addresses a 5 billion USD serviceable market and intends to set a strong footprint.
About Genomic Vision
Genomic Vision is a biotechnology company that develops products and services for the highly accurate characterization of genome modifications. We deliver high-quality integrated genomic analysis solutions to improve quality control and bioproduction standards of advanced gene therapies at scale. Based on molecular combing technology and artificial intelligence, The Company provides robust quantitative measurements needed for high confidence characterization of transformed cell lines and prediction of cell line performance, in particular in the context of the biomanufacturing processes of cell and gene therapies. Genomic Vision’s molecular combing technology has further applications in drug development of agents targeting DNA replication and damage response mechanisms, visualizing DNA replication kinetics and telomere length maintenance. Genomic Vision, based near Paris in Bagneux, is a public company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).
Forward Looking Statement
This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section of the universal registration document filed with the AMF on April 28, 2023 under number D.23-0383, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.
This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.
Genomic Vision has set up a financing line in the form of convertible notes with warrants (OCABSA) with its Financing partner.
The shares resulting from the conversion or exercise of the aforementioned securities will, in general, be sold on the market, which could create downward pressure on the share price as well as a dilution.
Shareholders could therefore suffer a loss of their invested capital due to a significant decrease in the value of the company's shares. The company has carried out several dilutive financing operations, and investors are advised to be very careful before making a decision to invest in the company's securities.
Consilium Strategic Communications
International Investor Relations & Strategic Communications
+44 (0) 20 3709 5700
Member of the CAC® Mid & Small and CAC® All-Tradable indices
Keywords: Manufacturing Industry; Manufacturing and Industrial Facilities; Cell- and Tissue-Based Therapy; Genetic Therapy; Genomics; Clone Cells; DNA Replication; Cell Line; Cell Line, Transformed; Recombinant Proteins; Cell Line Development; DNA Copy Number Variations; Clone Cells; Drug Development; Biological Products; Productivity; Technology; Biotechnology; Commerce; France
Published by B3C newswire